Inovio Pharmaceuticals (INO) Q4 2025 earnings summary

Executive summary

• BLA for INO-3107 accepted by FDA for review under the Accelerated Approval Program, with a PDUFA target date of October 30, 2026; FDA raised questions about eligibility for accelerated approval, with a meeting pending.

• Commercial preparations for INO-3107 are well advanced, including resource optimization, pricing strategy, market segmentation, and selection of key partners.

• Pipeline progress includes partnerships for glioblastoma, new clinical collaborations, and ongoing development of next-generation DNA medicine candidates such as DMAbs and DPROT.

• Published positive immunological and long-term clinical data for INO-3107 in Nature Communications and The Laryngoscope, showing reduced need for surgery in RRP patients.

Financial highlights

• Cash, cash equivalents, and short-term investments were $58.5 million at year-end 2025, down from $94.1 million at the end of 2024.

• Operating expenses decreased 23% year-over-year, from $112.6 million in 2024 to $86.9 million in 2025.

• Net income for Q4 2025 was $3.8 million, driven by a $21.2 million non-cash gain on warrant liability adjustment; full-year 2025 net loss was $84.9 million.

• No debt and projected cash runway into Q4 2026.

• R&D and G&A expenses for FY2025 were $54.2M and $32.7M, both down from 2024.

Outlook and guidance

• Focus remains on achieving FDA approval for INO-3107 and extending cash runway to support a potential 2026 launch.

• Cash runway projected into Q4 2026, with Q1 2026 net cash burn projected at $22 million; projections exclude potential capital-raising activities.

• Additional pipeline progress and partnerships are planned, dependent on approval and available financial resources.